Why the study?
Does aspirin reduce cardiovascular events and myocardial infarctions in primary prevention populations?
Population
Meta-analysis of four randomised controlled trials of aspirin for primary prevention of coronary heart disease
Design
Meta-analysis
Authors
Loading...
Supports aspirin in primary prevention only at coronary risk ≥1.5%/year; challenges routine use at lower risks where bleeding predominates.
Does aspirin reduce cardiovascular events and myocardial infarctions in primary prevention populations?
Aspirin for primary prevention provides a net benefit at a coronary event risk of ≥1.5%/year, but the risk of bleeding outweighs benefits at a risk of 0.5%/year.
P. S Sanmuganathan (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: